

4. Turco S, King RE. *Sterile Dosage Forms: Their Preparation and Clinical Application*. 3rd ed. Philadelphia: Lea & Febiger, 1987:267–269.
5. *Monoclonal Therapeutics and Companion Diagnostic Products*, Report Code BIO016G, 2008, <http://www.bccresearch.com/report/BIO016G.html>.

BIBLIOGRAPHY

- Allen LV, Popovich NG, Ansel HC, eds. *Ansel's Pharmaceutical Dosage Forms and Delivery Systems*. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
- Ahern TJ, Manning MC, eds. *Stability of Protein Pharmaceuticals*, Part A and Part B books. New York: Plenum, 1992.
- Akers MJ. Antioxidants in pharmaceutical products. *J Parenter Sci Technol* 1982; 36:222–228.
- Akers MJ. Considerations in selecting antimicrobial preservative agents for parenteral product development. *Pharm Tech* 1984; 8:36–46.
- Akers MJ, Fites AL, Robison RL. Formulation design and development of parenteral suspensions. *J Parenter Sci Technol* 1987; 41:88–96.
- Akers MJ. Parenterals: Small volume. In: Swarbrick J and Boylan J, eds. *Encyclopedia of Pharmaceutical Technology*. New York: Dekker, 1995.
- Akers MJ, DeFelippis MR. Formulation of protein dosage forms: Solutions. In: Hovgaard L, Frokjaer S, eds. *Pharmaceutical Formulation Development of Peptides and Proteins*. London, UK: Taylor & Francis, 2000.
- Akers MJ. Excipient-drug interactions in parenteral formulations. *J Pharm Sci* 2002; 91:2283–2297.
- Akers MJ. Parenterals. In: *Remington's Pharmaceutical Sciences*. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:802–836.
- Bontempo J, ed. *Development of Parenteral Biopharmaceutical Dosage Forms*. New York: Marcel Dekker, 1997.
- Boylan JC, Fites AL, Nail SL. Parenteral Products. In: Banker GS and Rhodes CT, eds. *Modern Pharmaceutics*. 3rd ed. New York: Dekker, 1995:chap 12.
- Carpenter JF, Crowe JH. The mechanism of cryoprotection of proteins by solutes. *Cryobiology* 1988; 25: 244–250.
- Carpenter JF, Pikal MJ, Chang BS, et al. Rational design of stable lyophilized protein formulations: Some practical advice. *Pharm Res* 1997; 14:969–975.
- Carpenter JF, Chang BS, Garzon-Rodriguez W, et al. Rational design of stable lyophilized protein formulations: Theory and Practice. In: Carpenter JF, Manning MC, eds. *Rational Design of Stable Protein Formulations*. New York: Kluwer Academic, 2002.
- DeFelippis MR, Akers MJ. Formulation, manufacture, and control of protein suspension dosage forms. In: Hovgaard L, Frokjaer S, eds. *Pharmaceutical Formulation Development of Peptides and Proteins*. London, UK: Taylor & Francis, 2000.
- ICH: Q8(R2): *Pharmaceutical Development*, <http://www.fda.gov/cder/guidance/index.htm>. Accessed August 2009.
- Nail SL, Akers MJ, eds. *Development and Manufacture of Protein Pharmaceuticals*. New York: Kluwers-Plenum, 2002.
- Nema S, Ludwig J, eds. *Pharmaceutical Dosage Forms: Parenteral Medications*. 3rd ed. 3 vols. New York, NY: Informa Healthcare, 2010.
- Pearlman R, Wang YJ, eds. *Formulation, characterization, and stability of protein drugs*, Vol 9. In: Borchardt R, series ed. *Pharmaceutical Biotechnology*, New York: Plenum, 1995.
- Sinko PJ, ed. *Martin's Physical Pharmacy and Pharmaceutical Sciences*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
- Tonnesen HH, ed. *Photostability of Drugs and Drug Formulations*. Boca Raton, FL: CRC Press, 2004.
- Wang YJ, Pearlman R, eds. *Stability and characterization of protein and peptide drugs*. Vol 5. In: Borchardt R, series ed. *Pharmaceutical Biotechnology*. New York: Plenum, 1993.